VF
IBRX icon

Virtu Financial’s ImmunityBio IBRX Stock Holding History

Virtu Financial’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.01M Buy
+262,298
New +$1.8M 0.08% 154
2024
Q4 		– Sell
-13,608
Closed -$51K – 1764
2024
Q3 		$51K Buy
+13,608
New +$63K ﹤0.01% 1006
2024
Q2 		– Sell
-11,285
Closed -$61K – 1555
2024
Q1 		$61K Sell
11,285
-49,184
-81% -$223K ﹤0.01% 991
2023
Q4 		$304K Buy
+60,469
New +$190K 0.02% 601
2022
Q2 		– Sell
-13,190
Closed -$74K – 1789
2022
Q1 		$74K Sell
13,190
-17,060
-56% -$105K 0.01% 1041
2021
Q4 		$184K Buy
30,250
+10,123
+50% +$76.1K 0.02% 866
2021
Q3 		$196K Buy
+20,127
New +$221K 0.02% 923
2021
Q2 		– Sell
-22,195
Closed -$527K – 1758
2021
Q1 		$527K Buy
+22,195
New +$575K 0.04% 498
2019
Q3 		– Sell
-21,596
Closed -$22K – 1587
2019
Q2 		$22K Buy
+21,596
New +$24.9K ﹤0.01% 1337
2018
Q4 		– Sell
-10,305
Closed -$38K – 1741
2018
Q3 		$38K Buy
+10,305
New +$32.6K ﹤0.01% 1337
2018
Q2 		– Sell
-46,313
Closed -$180K – 2214
2018
Q1 		$180K Buy
+46,313
New +$203K 0.01% 1401

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Virtu Financial's IBRX Position: Q1 2026 in Review

Virtu Financial opened a new position in ImmunityBio (IBRX) in Q1 2026: 262,298 shares worth $2.01M. The stake represents 0.08% of the portfolio and ranks #154 among its holdings. This is a return to the name: Virtu Financial previously reported a position in IBRX as recently as Q3 2024.

Virtu Financial first reported a position in IBRX in Q1 2018 and has held it in 11 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Virtu Financial held 262,298 shares of ImmunityBio worth $2.01M as of Q1 2026.
  • ImmunityBio was a new Virtu Financial position in Q1 2026.
  • ImmunityBio made up 0.08% of Virtu Financial's portfolio in Q1 2026, its #154 holding.
  • Virtu Financial first reported a position in ImmunityBio in Q1 2018 and has held it in 11 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.